Bridgebiocology Therapeut Ownership
$2.14
8.94%
Nasdaq, Nov 13, 04:00 pm EST.
Closed.
Why the stock moved
Industry
Bridgebiocology Therapeut Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Cormorant Asset Management, LP
|
17.879m | 22.31% | — | Jul 01 2026 |
| 2 |
BridgeBio Pharma, Inc.
INSIDER
|
14.590m | 18.21% | +784.720k | Oct 10 2025 |
| 3 |
Deerfield Management Company, L.P.
|
4.885m | 6.10% | — | Jun 30 2026 |
| 4 |
BC Global Opportunities IX LP
|
4.366m | 5.45% | +3.266m | Sep 04 2025 |
| 5 |
Omega Fund Management, LLC
|
3.290m | 4.11% | — | Jun 30 2026 |
|
1
Cormorant Asset Management, LP
|
22.31%
17.879m
|
|
2
BridgeBio Pharma, Inc.
INSIDER
|
18.21%
14.590m
|
|
3
Deerfield Management Company, L.P.
|
6.10%
4.885m
|
|
4
BC Global Opportunities IX LP
|
5.45%
4.366m
|
|
5
Omega Fund Management, LLC
|
4.11%
3.290m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 56.18% of Bridgebiocology Therapeut, with Cormorant Asset Management, LP the biggest at 22.31%, followed by BridgeBio Pharma, Inc. (18.21%) and Deerfield Management Company, L.P. (6.10%). |
Bridgebiocology Therapeut Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
